moleculin.com - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi MBRX

Moleculin Biotech, Inc. (MBRX) develops agents to overcome cancer cell defenses, including the fight against leukemias via Annamycin technology. The company's EBITDA statistics confirm a lack of operational inflow, as 0.00 is recorded as the baseline value. Current momentum is supported only by legacy capital while developments undergo testing. Meanwhile, the strategy across various tumor types minimizes the risk of investment loss.

MBRX: Bathi sadurunge mbayar bunga, pajak, lan amortisasi Moleculin 23.11.2025 - 12.11.2026

Moleculin Biotech - rincian analitis lan metrik utama (MBRX)

- nilai pasar lan prakiraan target analis:

Rega bursa Moleculin Biotech Inc|MBRX - Target konsensus

- rincian nilai pasar emiten:

Nilai pasar Moleculin Biotech|MBRX - Nilai Total Perusahaan

- informasi kapitalisasi buku:

Nilai Buku Saham Moleculin Biotech|MBRX - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku moleculin.com|MBRX - Total Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Total Utang marang Modal Moleculin Biotech, Inc.|MBRX - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Moleculin Biotech Inc|MBRX - Gunggung utang perusahaan|Rasio utang-utang marang kapitalisasi buku Moleculin Biotech|MBRX - Utang jangka dawa perusahaan|Utang jangka cendhak Moleculin Biotech|Rasio jangkoan perantara moleculin.com

- informasi bathi lan kelipatan valuasi:

MBRX - Bathi resik perusahaan|Bathi mangsa ngarep Moleculin Biotech, Inc.|MBRX - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Moleculin Biotech Inc|MBRX - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Moleculin Biotech|MBRX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Moleculin Biotech|MBRX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan moleculin.com|MBRX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Moleculin Biotech, Inc.

Ringkesan analitik perusahaan:Moleculin Biotech, Inc., MBRX

The development of innovative oncology platforms by Moleculin Biotech, Inc. (MBRX) requires precise monitoring of cash flows stripped of the impact of depreciation and credit obligations. This metric captures the real operational efficiency of the business, allowing users to track actual liquidity between quarterly reports and assess the funding stability of leukemia drug clinical trials via the EBITDA history on the GURU.Markets platform.

Pesaing Moleculin Biotech, Inc. (MBRX)

Geron Bio (GERN) - Bathi sadurunge bunga, pajak, lan amortisasi|NBTX: Bathi operasional sadurunge ngurangi amortisasi|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi BCYC (bicycletherapeutics.com)|CytomX Therapeutics, Inc. (CTMX) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi CATX (Perspective Therapeutics, Inc.)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Genelux Corp.|Bathi sadurunge mbayar bunga, pajak, lan amortisasi MOLN|Bathi operasional EBITDA ONCY|Bathi operasional EBITDA lisata.com (LSTA)|Galera Therapeutics, Inc. - Bathi operasional sadurunge ngurangi amortisasi|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi MTEM (Molecular Templates Inc)